Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Overview
Bio-Techne Corporation (NASDAQ: TECH) is a globally recognized life sciences company offering innovative bioactive reagents, consumables, and instruments. Its extensive portfolio supports a broad spectrum of applications in clinical diagnostics, drug discovery, and biological research. Using advanced immunoassays, spatial biology tools, and protein analysis reagents, Bio-Techne equips scientists with the essential resources to investigate complex biological processes and disease mechanisms.
Core Business Areas
Bio-Techne organizes its operations into two primary segments:
- Protein Sciences: This segment supplies specialized reagents such as antibodies, cytokines, and growth factors, along with analytical instruments, that serve as critical tools for protein analysis and cell biology. These products are employed in both basic and advanced research settings, reflecting a strong commitment to scientific precision and reproducibility.
- Diagnostics and Spatial Biology: Focused on clinical diagnostic solutions, this segment offers molecular tests, diagnostic reagents, and spatial biology products. These tools facilitate reliable clinical assays, supporting translational research and precision medicine through enhanced imaging and biomarker analysis.
Global Reach and Market Position
Based in Minnesota, Bio-Techne has established a significant market presence globally. Its products are widely used in North America, Europe, the Middle East, Africa, the UK, and Asia-Pacific. This international footprint, combined with a deep and diverse product catalog, positions the company as a key contributor to high-quality scientific research and diagnostic testing worldwide.
Innovation and Strategic Collaborations
Innovation is at the core of Bio-Techne’s operations. The company invests heavily in research and development to integrate emerging technologies, such as AI-assisted protein design and automated spatial biology platforms, into its product lines. Strategic collaborations with academic institutions, industry partners, and regional distributors further enhance its capabilities and propel breakthrough innovations. These partnerships not only accelerate product development but also ensure that the tools provided are seamlessly integrated into existing research and clinical workflows.
Product Portfolio and Revenue Streams
Bio-Techne offers an extensive inventory of bioactive reagents and research tools. Its products cater to a wide array of scientific needs ranging from basic research to clinical diagnostics. By providing both Research Use Only (RUO) and Good Manufacturing Practice (GMP) grade products, the company meets the rigorous demands of biotechnology, pharmaceutical, and academic sectors. Its revenue is generated through direct sales, licensing agreements, and strategic distribution deals, all of which underscore the company’s role as a pivotal enabler of scientific exploration.
Competitive Landscape
In a crowded marketplace, Bio-Techne stands out by leveraging its robust product portfolio, cutting-edge technological integration, and a proven track record of intellectual property innovation. While competitors offer similar life sciences tools, Bio-Techne differentiates itself with high-quality, reliable products and ongoing legal protections that reinforce its investment in research and development.
Customer Focus and Operational Excellence
The company prioritizes customer success by delivering reproducible and high-performance research tools that enhance scientific discovery. It regularly engages with the scientific community through educational workshops, technical discussions, and industry events, ensuring its customers remain at the forefront of innovation. This commitment to operational excellence has solidified Bio-Techne’s reputation as a trusted partner in both research and clinical diagnostic communities.
Conclusion
Overall, Bio-Techne Corporation is a cornerstone in the life sciences industry. Through its dual focus on Protein Sciences and Diagnostics & Spatial Biology, the company provides essential tools and innovative solutions that empower researchers and clinicians alike. Its global reach, strategic collaborations, and continuous push for technological advancement highlight its pivotal role in advancing biomedical research and clinical diagnostics.
Bio-Techne (NASDAQ: TECH) has announced it will host a conference call and webcast on February 5, 2025, at 8:00 a.m. CST to discuss its second quarter fiscal 2025 financial results. Participants can join via phone by dialing 1-877-407-9208 (domestic) or 1-201-493-6784 (international) using Conference ID 13751305. The event will also be accessible through a webcast on the company's investor relations website.
For those unable to attend live, a recorded rebroadcast will be available from 11:00 a.m. CST on February 5 until 11:00 p.m. CST on March 5, 2025. The replay can be accessed by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international).
ScaleReady has awarded a $300,000 G-Rex® Grant to BrainChild Bio to support the development of BCB-276, an autologous CAR-T therapy for treating diffuse intrinsic pontine glioma (DIPG), an incurable pediatric brain tumor. The grant is part of ScaleReady's $20M initiative to advance cell and gene-modified cell therapy development.
BrainChild Bio plans to advance BCB-276 into a multi-center Phase 2 pivotal clinical trial in 2025. The grant will help optimize their G-Rex based CAR-T cell manufacturing process, offering process simplicity, consistency, and flexibility. Additionally, BrainChild Bio will have the option to evaluate CellReady's standardized 7-day CAR-T cell process, which uses closed system G-Rex bioreactors and Bio-Techne's ProPak GMP cytokines.
Bio-Techne (NASDAQ: TECH) has announced the launch of new AI-engineered designer proteins through its R&D Systems brand. The expanded portfolio includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (available in both RUO and GMP formats), and three Wnt/RSPO Agonist proteins.
These innovative proteins are specifically engineered using advanced AI-based design platforms and protein evolutionary workflows to enhance cellular therapy processes and research applications. The products feature improved functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability, leveraging generative AI trained on nearly five decades of proteomic leadership.
The new proteins are designed to address critical needs in cell culture performance and optimization, particularly in cellular therapy applications, stem cell research, organoid development, and regenerative medicine.
Bio-Techne (NASDAQ: TECH) announced its participation at Phacilitate's Advanced Therapies Week, scheduled for January 20-23, 2025, in Dallas, Texas. The company will showcase its new ProPak™ GMP cytokines and cell and gene therapy solutions at booth 517.
Key highlights include the integration of ProPak liquid GMP cytokines with Wilson Wolf's G-Rex® bioreactor through ScaleReady, offering a closed process solution for T cell manufacturing. The company will also display the Ella™ automated ELISA platform and Simple Plex™ assays for QC release testing.
Dr. David Hermanson, Principal Scientist, will deliver a breakout session on closed system manufacturing on January 21 and host a product demonstration on January 22, focusing on ProPak cytokines integration in T cell manufacturing workflows. Will Geist, President of Bio-Techne's Protein Sciences Segment, emphasized the company's commitment to efficient manufacturing of cell and gene-modified cell therapies.
ScaleReady has awarded a $125,000 G-Rex Grant to Seattle Children's Therapeutics, a division of Seattle Children's Research Institute. The grant will support the integration of advanced technologies into their CAR-T cell platform, which has already utilized G-Rex bioreactors to manufacture cell therapy products for hundreds of clinical trial participants.
As part of the grant, Seattle Children's Therapeutics will explore fully closed G-Rex bioreactors and Bio-Techne's GMP-grade cytokines to optimize manufacturing for future trials. They will also receive early access to G-Rex product development and participate in evaluating new devices, including cell separation technology that isolates T-cells without expensive instrumentation.
This grant is part of ScaleReady's larger $20M initiative to advance cell and gene-modified cell therapy development and manufacturing, with individual grants worth up to $300,000.
Bio-Techne (NASDAQ: TECH) has won another legal case against Miltenyi Biotec in the Cologne Regional Court, Germany, regarding the unauthorized reverse engineering of Bio-Techne's proprietary NKG2C/CD159c antibodies. The court found that Miltenyi's antibodies had 100% identical variable regions to Bio-Techne's R&D Systems branded products.
This victory follows a similar 2023 case where Miltenyi was found to have reverse engineered Bio-Techne's TIGIT and CCR-7 antibodies. The court has awarded Bio-Techne monetary damages for sales of the reverse engineered antibodies, reimbursement of costs for demonstrating copying, and rights to additional information about Miltenyi's unlawful activities. Miltenyi retains the right to appeal the ruling.
Bio-Techne (NASDAQ: TECH) has announced that its President and CEO, Kim Kelderman, will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 10:30 a.m. PST. Interested parties can access a live webcast of the presentation through Bio-Techne's Investor Relations website's IR Calendar page.
Bio-Techne (NASDAQ: TECH) has announced a strategic co-marketing and co-promotion agreement with Waters to enhance biotherapeutic characterization and development processes. The partnership combines Bio-Techne's MauriceFlex™ System for charge separation with Waters' BioAccord™ LC-MS System for liquid chromatography mass spectrometry.
The collaboration has already yielded joint activities in late 2024, including an application note, webinar, and presentations at major conferences such as CASSS MS, Festival of Biologics, and PEGS EU. Scientists from both companies are currently working on analyzing additional biomolecule classes, with plans to showcase results at upcoming scientific conferences through various formats including application notes and webinars.
ScaleReady, along with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a G-Rex® Grant to Moonlight Bio to support their CAR T cell therapy development for solid tumors. The grant is part of ScaleReady's $20M initiative to advance cell and gene-modified cell therapy development.
The grant provides Moonlight Bio with access to a commercial CAR T manufacturing platform, funding for IND-enabling studies validation runs, Bio-Techne's ProPak™ and GMP Cytokines, and optional analysis of manufacturing batch records by CellReady. Individual grants are worth up to $300,000.
Moonlight Bio's technology is based on research published in Nature, focusing on enhancing engineered T cell therapies by utilizing mutations from T cell malignancies.
Bio-Techne (NASDAQ: TECH) has announced a new distribution partnership with MedSanTek to expand its product reach across Turkey and Azerbaijan. The agreement enables MedSanTek to distribute Bio-Techne's portfolio of brands including R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics, and Asuragen.
MedSanTek, founded in the late 2000s, is a leading in vitro diagnostics and research products distributor in the region, specializing in molecular biology, immunology, cancer research, and cell therapy. The partnership aims to leverage MedSanTek's local market expertise and distribution network to enhance Bio-Techne's presence in Turkey and Azerbaijan's biotechnology, laboratory, and hospital sectors.
FAQ
What is the current stock price of Bio-Techne (TECH)?
What is the market cap of Bio-Techne (TECH)?
What are the primary business segments of Bio-Techne Corporation?
How does Bio-Techne support scientific research?
What distinguishes Bio-Techne in a competitive market?
Who are the main customers of Bio-Techne Corporation?
How does Bio-Techne ensure product quality and reliability?
What role do strategic partnerships play for the company?
Can you describe the global presence of Bio-Techne?
